BMS-790052 with Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects with Chronic Hepatitis C Genotype 1

-
Investigator: Mandana Khalili, MD
Sponsor: Bristol-Myers Squibb Company

Location(s): Egypt; Sweden; Mexico; Puerto Rico; Canada; Australia

Description

At least 1 dose of BMS-790052 combined with Standard of Care (pegylated interferon and ribavirin) can be identified which is safe, well tolerated, and demonstrates extended rapid virologic response rates at least 35% greater than placebo.

Primary Outcome Measures

  • Antiviral activity, as determined by the proportion of HCV genotype 1 subjects with extended rapid virologic response, defined as undetectable HCV RNA
  • Antiviral activity, as determined by the proportion of HCV genotype 1 subjects with 24-week sustained virologic response, defined as undetectable HCV RNA
  • Safety, as measured by the frequency of Serious Adverse Events and discontinuations due to Adverse Events 

Secondary Outcome Measures

  • To assess the proportion of HCV genotype 1 subjects with rapid virologic response, ie, undetectable HCV RNA 
  • To assess the proportion of HCV genotype 1 subjects with complete early virologic response, ie, undetectable HCV RNA
  • To assess the proportion of HCV genotype 1 subjects with 12-week sustained virologic response, ie, undetectable HCV RNA 
  • To describe resistant variants associated with virologic failure

Enrollment: 395